Oppenheimer initiated coverage on ArriVent BioPharma with a new price target

7/22/24 7:50:34 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer initiated coverage of ArriVent BioPharma with a rating of Outperform and set a new price target of $35.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVBP

Date	Price Target	Rating	Analyst
3/20/2025	$37.00	Buy	B. Riley Securities
3/10/2025	$45.00	Buy	Guggenheim
7/22/2024	$35.00	Outperform	Oppenheimer
4/30/2024	$25.00	Buy	H.C. Wainwright
2/20/2024	$35.00	Buy	Jefferies
2/20/2024	$27.00	Buy	Goldman
2/20/2024	$30.00	Buy	Citigroup